CXCL9 and juvenile idiopathic arthritis: Serum IL-18 levels are also useful for the prediction of treatment outcomes in patients with s-JIA treated with canakinumab (CAN) in combination with serum interferon (IFN)-γ levels and chemokine (C-X-C motif) ligand 9 (CXCL9) levels (21).